New data on Radicava for people with ALS presented at ENCALS

The US unit of Japan’s Mitsubishi Tanabe Pharma has announced results from two studies of its already marketed Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) at the European Network to Cure Amyotrophic Lateral Sclerosis (ENCALS) 2024 meeting.

Findings from an ongoing real-world study utilizing information in the ALS/MND Natural History Study Consortium (Consortium) database of people living with ALS initiating treatment with Radicava suggest an additional survival benefit of 3.2 months with Radicava ± riluzole compared to treatment with riluzole alone.

Separately, positive results from Study MT-1186-A03 (NCT04577404), a Phase III study evaluating the long-term safety of Radicava ORS, showed no new safety concerns and that Radicava ORS was well-tolerated during the 96-week study period.